ArticleThe Laryngoscope2025
The Role of Tumor Budding in Early-Stage Laryngeal Cancer Treatment Selection.
Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Tumor Budding in Early-Stage Laryngeal Cancer Treatment Selection.The Laryngoscope · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveLaryngeal cancer is a prevalent malignant neoplasm, with early-stage glottic tumors treated with surgery or radiotherapy. Radioresistance significantly complicates treatment, highlighting the necessity for early detection methods. This study aimed to evaluate the relationship between tumor budding and radiotherapy outcomes in affected patients.
methodsThis investigation encompassed patients diagnosed with early-stage squamous cell carcinoma of the glottic larynx who received radiotherapy and had a minimum follow-up of 1 year. Pathological specimens collected at diagnosis were reassessed for tumor budding. The data were analyzed to determine the best cut-off value for tumor budding to predict radioresistance and differences in survival based on tumor budding cut-off value.
resultsThe study cohort comprised 49 patients who met the pre-established criteria. The radioresistant group comprised 14 patients. All except one patient were male (mean age: 64 years). The best cut-off value for tumor budding was determined as 2. Patients categorized into high risk (tumor budding ≥ 2) had a significantly higher chance of radiotherapy failure than those with low risk (tumor budding < 2, AUC = 0.696; p = 0.034; sensitivity = 78.6%; specificity = 62.9%). The high risk group also had a significantly reduced 5-year disease-free survival compared to the low risk group (p = 0.008). Overall survival was similar.
conclusionThe prognosis for early-stage glottic laryngeal cancer is generally favorable, yet a standardized risk stratification tool for treatment selection remains lacking. Tumor budding assessment in routine histopathology could help identify patients at higher risk of recurrence, guiding decisions on radiotherapy intensity and post-treatment surveillance. Integrating tumor budding into clinical practice may support more personalized treatment strategies, ultimately improving patient outcomes. LEVEL OF EVIDENCE: 3:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.